NEW YORK, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)HEREDITARY NEUROPATHY FOUNDATION INC, founded in 2001, is a small nonprofit in the Medical Research sector that reported $545K in total revenue in fiscal year 2024. Revenue decreased 17% compared to the prior year. Expenses of $895K exceeded revenue, resulting in a 64% operating deficit.
HNF, INC., A NON-PROFIT DEDICATED TO SUPPORTING PROJECTS THROUGH THE THERAPEUTIC RESEARCH IN ACCELERATED DISCOVERY (TRIAD)PROGRAM, A COLLABORATIVE EFFORT WITH ACADEMIA, GOVERNMENT AND INDUSTRY, TO DEVELOP TREATMENTS FOR CMT. CURRENTLY TRIAD INVOLVES MANY GROUPS THAT SPAN THE DRUG DISCOVERY, DRUG DEVELOPMENT, AND DIAGNOSTICS CONTINUUM. EDUCATION AND SUPPORT OF THE CMT COMMUNITY TO IMPROVE QUALITY OF LIFE IS ALSO A KEY COMPONENT OF HNF'S MISSION.
RESEARCH PROGRAMS ARE AS FOLLOWS: THERAPEUTIC RESEARCH IN ACCELERATED DISCOVERY (TRIAD) CONTINUES TO SERVE AS HNF'S PRIMARY TRANSLATIONAL RESEARCH ACCELERATOR, SUPPORTING THE DEVELOPMENT OF ESSENTIAL...
RESEARCH PROGRAMS ARE AS FOLLOWS: THERAPEUTIC RESEARCH IN ACCELERATED DISCOVERY (TRIAD) CONTINUES TO SERVE AS HNF'S PRIMARY TRANSLATIONAL RESEARCH ACCELERATOR, SUPPORTING THE DEVELOPMENT OF ESSENTIAL RESEARCH TOOLS (INCLUDING IPSCS AND ANIMAL MODELS), THERAPEUTIC CANDIDATES, DRUG SCREENING INITIATIVES, GENE THERAPY PROGRAMS, AND DIGITAL HEALTH TECHNOLOGY INNOVATIONS. THE PROGRAM MAINTAINS STRONG PARTNERSHIPS WITH ACADEMIC INSTITUTIONS, REGULATORY AGENCIES, AND INDUSTRY COLLABORATORS AND ADVANCES KEY SCIENTIFIC INITIATIVES IN BIOMARKER DEVELOPMENT, CLINICAL ENDPOINT REFINEMENT, AND THERAPY TRANSLATION. TRIAD ALSO LEADS THE ANNUAL CMT CLINICAL TRIAL READINESS SUMMIT, WHICH BRINGS TOGETHER GLOBAL EXPERTS TO ALIGN ON REGULATORY EXPECTATIONS, OPTIMIZE TRIAL DESIGN, AND ACCELERATE THERAPY DEVELOPMENT. THE GLOBAL REGISTRY FOR INHERITED NEUROPATHIES (GRIN) CONTINUES TO GROW AS AN INTERNATIONAL CMT PATIENT REGISTRY, CAPTURING NATURAL HISTORY DATA AND PROVIDING COMPREHENSIVE PATIENT-REPORTED, CLINICAL, DIGITAL, AND GENETIC DATASETS. GRIN PLAYS A CRITICAL ROLE IN CLINICAL TRIAL READINESS, SUPPORTING FEASIBILITY ASSESSMENTS, ENDPOINT DEVELOPMENT, AND PATIENT RECRUITMENT FOR THERAPEUTIC DEVELOPMENT PROGRAMS. GRIN INSIGHTS AND DATA INFRASTRUCTURE INFORM KEY SESSIONS AND WORKING GROUPS AT THE CMT CLINICAL TRIAL READINESS SUMMIT, HELPING RESEARCHERS AND INDUSTRY PARTNERS ADDRESS UNMET NEEDS AND STRENGTHEN FUTURE TRIAL STRATEGIES. THE CMT BIOBANK CONTINUES TO EXPAND ITS PATIENT SAMPLE COLLECTION, INCLUDING BLOOD, SALIVA, TISSUE, SKIN FIBROBLASTS, IPSCS, AND OTHER BIOSPECIMENS DONATED BY INDIVIDUALS WITH CMT. THESE SAMPLES ARE PROCESSED AND STORED UNDER STRICT QUALITY-CONTROLLED PROTOCOLS AND REMAIN SECURELY LINKED TO GRIN CLINICAL, DIGITAL, AND GENETIC DATA. THIS INTEGRATED RESOURCE SUPPORTS PRE-COMPETITIVE BIOMARKER DISCOVERY, MOLECULAR RESEARCH, AND DIGITAL BIOMARKER VALIDATION, ENABLING RESEARCHERS AND INDUSTRY PARTNERS TO ACCELERATE THERAPEUTIC DEVELOPMENT. FINDINGS AND COLLABORATIVE OPPORTUNITIES FROM THE BIOBANK ARE REGULARLY HIGHLIGHTED AT THE CMT CLINICAL TRIAL READINESS SUMMIT, WHERE CROSS-SECTOR PARTNERS ALIGN ON BIOMARKER PRIORITIES AND STRATEGIES TO ADVANCE FUTURE TREATMENTS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $545,418 | $655,296 | -0.2% |
| Expenses | $894,903 | $730,003 | +0.2% |
| Net Income | $-349,485 | $-74,707 | +3.7% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ALLISON MOORE | FOUNDER AND CHIEF EXECUTIV | 50.00 |
Officer
Director
|
$0 | $52,675 | $52,675 |
| KARA SPRAGUE | TREASURER | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| MATTHEW DOWNING | CHAIRMAN | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| KERIN REILLY | BOARD MEMBER | 5.00 |
Director
|
$0 | $0 | $0 |
| GRETCHEN CAPPIELLO | BOARD MEMBER | 5.00 |
Director
|
$0 | $0 | $0 |
| BROOKE WARREN | SECRETARY | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| ROBERT KAUFFMAN | BOARD MEMBER | 5.00 |
Director
|
$0 | $0 | $0 |
| DOMINIC HADEED | BOARD MEMBER | 5.00 |
Director
|
$0 | $0 | $0 |
| SITAL BHAVSAR | BOARD MEMBER | 5.00 |
Director
|
$0 | $0 | $0 |
| NATALIA SALEJKO | BOARD MEMBER | 5.00 |
Director
|
$0 | $0 | $0 |
| DENNIS SULLIVAN | BOARD MEMBER | 5.00 |
Director
|
$0 | $0 | $0 |
| POYA GHASRI | BOARD MEMBER | 5.00 |
Director
|
$0 | $0 | $0 |
| COURTNEY HOLLETT | EXECUTIVE DIRECTOR | 40.00 |
Officer
|
$75,000 | $0 | $75,000 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $545,418 | $894,903 | $1,016,066 | $-349,485 |
| 2024 | $655,296 | $730,003 | $1,503,541 | $-74,707 |
| 2023 | $543,625 | $671,491 | $1,515,448 | $-127,866 |
| 2022 | $1,259,879 | $759,374 | $1,627,053 | $500,505 |
| 2021 | $637,088 | $679,388 | $1,295,654 | $-42,300 |
| 2020 | $912,443 | $623,754 | $1,301,620 | $288,689 |
| 2019 | $753,319 | $665,477 | $969,441 | $87,842 |
| 2018 | $483,801 | $518,886 | $909,104 | $-35,085 |
Compare HEREDITARY NEUROPATHY FOUNDATION INC with other nonprofits in New York and across the country.